Literature DB >> 11477731

Intratracheal administration of perfluorochemical-gentamicin suspension: a comparison to intravenous administration in normal and injured lungs.

C A Cox1, A B Cullen, M R Wolfson, T H Shaffer.   

Abstract

Respiratory infections can lead to acute lung injury and perfusion abnormalities. We hypothesized that intratracheal (IT) administration of a perfluorochemical (PFC) gentamicin (G) suspension as compared to intravenous (IV) administration of gentamicin will result in higher lung tissue levels of gentamicin, while maintaining safe serum levels. To test this hypothesis, 21 lambs with normal and acid injured lungs were studied for 4 hr, using 2 different drug delivery methods, IT and IV. Lungs were injured with warm HCl acid in saline lavage, followed by partial liquid ventilation with perflubron (bolus FRC = 20 mL/kg). G at a dose of 5 mg/kg was delivered either IT (G-PFC; 20 mL/kg) or IV (aqueous injection with IT 20 mL/kg PFC alone). Throughout the study, serum G levels, arterial blood gases, respiratory system compliance, and mean arterial blood pressure were measured. Lung tissue G levels were measured at 4 hr and averaged across lobes. Physiologic gas exchange and pulmonary function were maintained throughout the protocol for both the normal and injured lungs. Intravenously administered G resulted in an initial 5-min serum concentration of 43 +/- 2.5 mcg/mL, followed by an exponential decline over the 4-hr protocol to a level of 2.1 +/- 0.23 mcg/mL at hr 4. The intratracheally administered G suspension resulted in a 5-min serum concentration of 1.8 +/- 0.98 mcg/mL and remained relatively constant throughout the protocol, with a 4-hr level of 1.6 +/- 0.29 mcg/mL. With respect to lung tissue G levels, IT administration was significantly more effective in delivering the drug to the normal lungs than IV (31.4 +/- 3.3 mcg/g vs. 4.0 +/- 0.7 mcg/g) 4 hr after administration. In the lung injury group, there was a small but significant difference in lung tissue G levels, with the IT-administered perfluorochemical-G suspension achieving greater levels than the IV-administered G (11.9 +/- 0.52 mcg/g vs. 10.1 +/- 0.8 mcg/g). Additionally, the drug delivered IV and IT in both the normal and injured lung models was homogeneously distributed throughout the lung. These data show that G lung tissue levels in both normal and injured lungs were higher in the IT group when compared to IV administration. The results of this study demonstrate that in normal and injured lungs, homogeneous G lung tissue levels can be more effectively achieved at lower serum levels when delivered IT in a G-PFC suspension as compared to IV administration. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11477731     DOI: 10.1002/ppul.1100

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

1.  Targeted delivery of liquid microvolumes into the lung.

Authors:  Jinho Kim; John D O'Neill; N Valerio Dorrello; Matthew Bacchetta; Gordana Vunjak-Novakovic
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-31       Impact factor: 11.205

2.  Targeted delivery of inhalable drug particles in a patient-specific tracheobronchial tree with moderate COVID-19: A numerical study.

Authors:  Jianwei Wang; Ya Zhang; Xiaole Chen; Yu Feng; Xiaoyong Ren; Minjuan Yang; Ting Ding
Journal:  Powder Technol       Date:  2022-05-17       Impact factor: 5.640

Review 3.  Administration of Drugs/Gene Products to the Respiratory System: A Historical Perspective of the Use of Inert Liquids.

Authors:  Deepthi Alapati; Thomas H Shaffer
Journal:  Front Physiol       Date:  2022-05-10       Impact factor: 4.755

4.  Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.

Authors:  Ryan A Orizondo; Charlene Irvin Babcock; Mario L Fabiilli; Leonid Pavlovsky; J Brian Fowlkes; John G Younger; Keith E Cook
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-01-29       Impact factor: 2.849

5.  Perfluorochemical liquid-adenovirus suspensions enhance gene delivery to the distal lung.

Authors:  Jeffrey A Kazzaz; Marlene S Strayer; Jichuan Wu; Daniel J Malone; Hshi-Chi Koo; Thomas H Shaffer; Jonathan M Davis; David S Strayer; Marla R Wolfson
Journal:  Pulm Med       Date:  2011-08-18

6.  Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury.

Authors:  Marla R Wolfson; Perenlei Enkhbaatar; Satoshi Fukuda; Christina L Nelson; Robert O Williams; Soraya Hengsawas Surasarang; Sawittree Sahakijpijarn; Gennaro Calendo; Andrey A Komissarov; Galina Florova; Krishna Sarva; Steven I Idell; Thomas H Shaffer
Journal:  Clin Transl Med       Date:  2020-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.